A monoclonal antibody against annexin A2 targets stem and progenitor cell fractions in tumors

•Development of a novel antibody (termed as mAb150) developed in our lab which targets annexin A2.•Although there are earlier reports of another monoclonal antibody with the same target, the epitope recognized by mAb150 is novel.•mAb150 is specifically recognized to target the achilles heel of cancer viz. cancer stem cells and progenitors that persist after treatments and potentially give rise to minimal residual disease.